SCHEMBL2089949

SCHEMBL2089949

[CH2]OCC(=O)Nc1ccc(C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.66
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
HPGD P15428 1/20 0.59
RECQL P46063 1/20 0.59
MAPT P10636 3/20 0.58
HTT P42858 2/20 0.55
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL764569 0.83 HPGD (0.71) POLBKMT2AMEN1HPGDRECQL
SCHEMBL2098408 0.82 ALDH1A1 (0.65) KMT2AMEN1HPGDMAPTHTT
SCHEMBL2091472 0.81 ALDH1A1 (0.58) POLBKMT2AMEN1HPGDMAPT
SCHEMBL7511572 0.80 MEN1 (0.88) POLBKMT2AMEN1HPGDMAPT
SCHEMBL13841454 0.80 ALDH1A1 (0.73) POLBKMT2AMEN1HPGDRECQL
SCHEMBL31504023 0.80 MEN1 (0.88) POLBKMT2AMEN1HPGDMAPT
SCHEMBL8141144 0.80 POLB (1.00) POLBKMT2AMEN1HTTHDAC3
SCHEMBL12585104 0.79 POLB (0.61) POLBKMT2AMEN1HPGDRECQL
SCHEMBL16404380 0.79 POLB (0.61) POLBKMT2AMEN1HPGDRECQL
SCHEMBL7231081 0.79 POLB (0.73) POLBKMT2AMEN1HPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 POLB 757/4885KMT2A 3324/4885MEN1 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.